Tucotuzumab celmoleukin

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameTucotuzumab celmoleukin
Drug Alias Name西莫白介素单抗KS-interleukin-2西莫白介素-2-妥考妥珠单抗tucotuzumab celmoleukinatucotuzumab celmoleukine +[9] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionInterleukin-2 modulatorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects
TargetsInterleukin-2
Therapy Area/IndicationsUrinary Bladder NeoplasmsKidney NeoplasmsProstatic Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSwitzerland
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEmd Lexigen
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEmd Serono Inc
Active IndicationsN/A
Inactive IndicationsUrinary Bladder NeoplasmsKidney NeoplasmsProstatic Neoplasms +[7] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG